15/07/2026
While America Reschedules Cannabis and Opens the Door to Public Markets, Fiji Remains Stuck in the Past
By Cannabis Fiji
The global conversation around cannabis has changed.
Across much of the world, governments, regulators, investors, scientists, and healthcare professionals are increasingly approaching cannabis through the lenses of evidence, economics, medicine, and regulation rather than fear, stigma, and prohibition.
Nowhere is this shift more evident than in the United States.
In April 2026, the United States Department of Justice issued a final order moving FDA-approved ma*****na products and state-licensed medical ma*****na products into Schedule III under federal law.[1] While this does not constitute full legalization, it represents a significant departure from decades of federal policy that classified cannabis alongside substances deemed to have no accepted medical use.
More importantly, the discussion in America has evolved beyond whether cannabis should exist.
The conversation now centers on investment, taxation, medical research, patient access, economic development, regulatory frameworks, and participation in public financial markets.[2]
Meanwhile, Fiji continues to struggle with a policy position that appears increasingly disconnected from global realities.
The Contradiction at the Heart of Fiji's Cannabis Policy
The Fijian Government has already acknowledged the economic potential of cannabis.
Industrial h**p cultivation was legalized in 2022.[5]
Cabinet has approved the drafting of medicinal cannabis legislation, and consultations regarding a future medical cannabis industry have been ongoing.[3][4]
These actions represent an implicit admission that cannabis possesses legitimate agricultural, commercial, medicinal, and economic value.
Yet despite these acknowledgements, Fiji continues to criminalize ordinary citizens for activities involving the very same plant.
This contradiction has created a policy framework that sends mixed messages to both citizens and investors.
On one hand, government officials discuss investment opportunities, exports, and economic diversification.
On the other hand, citizens remain exposed to criminal penalties for cannabis possession under existing legislation.[6][7]
A modern policy framework cannot simultaneously portray cannabis as an economic opportunity and a criminal threat.
Eventually, governments must choose between evidence-based regulation and prohibition-based ideology.
The World Is Moving Forward
The significance of America's rescheduling efforts extends far beyond the United States.
As the world's largest economy and one of the world's most influential regulatory jurisdictions, American policy decisions often influence international attitudes toward medicine, banking, investment, and research.
The proposed movement of cannabis into Schedule III acknowledges what millions of patients, healthcare practitioners, and researchers have argued for decades:
Cannabis possesses recognized medical value.[1][8]
That reality has profound implications.
Expanded research opportunities.
Reduced barriers to investment.
Greater legitimacy for medical cannabis businesses.
Improved patient access.
Potential participation in public capital markets.
Enhanced economic activity.
These are the discussions occurring in major economies around the world.[2][10]
Fiji, meanwhile, remains trapped in debates that many nations settled years ago.
The Cost of Delay
Every year Fiji delays meaningful cannabis reform carries consequences.
Economic opportunities are lost.
Potential tax revenues disappear.
Agricultural diversification remains unrealized.
Investment capital flows elsewhere.
Research opportunities are missed.
Most importantly, patients continue waiting.
While other nations build regulatory frameworks capable of balancing public safety with economic development, Fiji continues to operate within a system that often appears reactive rather than strategic.
The result is not merely policy stagnation.
It is competitive disadvantage.
The global cannabis industry is no longer a theoretical future market.
It is a rapidly expanding international sector attracting billions in investment and generating employment across agriculture, manufacturing, healthcare, biotechnology, tourism, and retail.
Countries positioning themselves today are likely to become tomorrow's industry leaders.
Countries that hesitate may find themselves permanently behind.
Fiji Does Not Need to Follow America
Fiji should not blindly copy American policy.
Nor should it adopt reforms simply because other countries have done so.
What Fiji needs is a cannabis framework designed specifically for Fiji.
A framework that protects patients.
A framework that benefits local farmers.
A framework that respects indigenous landowners.
A framework that prevents monopolization by foreign interests.
A framework that generates economic opportunity while maintaining public safety.
However, creating such a framework requires acknowledging reality.
The global trend is unmistakable.
The future of cannabis policy is regulation.
The future of cannabis policy is science.
The future of cannabis policy is evidence.
The future of cannabis policy is economic participation.
The future of cannabis policy is not endless prohibition.
Conclusion
Fiji does not need to be the first nation to modernize cannabis policy.
But it cannot afford to remain among the last.
As America reschedules cannabis, expands medical recognition, and explores pathways that could further integrate cannabis-related businesses into mainstream financial systems, Fiji faces a choice.
It can continue defending policies rooted in the assumptions of the past.
Or it can begin building policies designed for the realities of the future.
History suggests that nations prosper when they adapt to changing realities rather than resist them.
The question is whether Fiji intends to lead, follow, or remain standing still while the rest of the world moves forward.
Yandra Mai Viti
Sign the petition for Cannabis Reform in Fiji: https://www.change.org/p/decriminalize-cannabis-in-fiji-for-our-health-wealth-and-justice?fbclid=IwdGRjcASd8_pjbGNrBJ3z9mV4dG4DYWVtAjExAHNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHnVgsDVvp6QXvfaCmTr89UQ0IVQlJp6WN75K8ibKY-LeMk7Yc-IRO9OecrEa_aem_YWdncwCgJ6hZLGC_F5i_v-2iJozx&brid=YWdncwFG04EuSVmGPz-bQ_JYajSC
References
[1] U.S. Department of Justice. (2026). Justice Department Places FDA-Approved Ma*****na Products and Products Containing Ma*****na Under Schedule III of the Controlled Substances Act.
[2] Reuters. (2026). Cannabis Rescheduling and Implications for Investment, Banking, and Public Markets.
[3] Government of Fiji Cabinet Decision. Approval for Drafting of Medicinal Cannabis Legislation.
[4] Fiji Medicinal Cannabis Industry Consultation and Feasibility Study Reports.
[5] Industrial H**p Act 2022 (Fiji).
[6] Illicit Drugs Control Legislation of Fiji.
[7] Public reporting and parliamentary discussion regarding cannabis-related criminal penalties in Fiji.
[8] U.S. Department of Health and Human Services Recommendation on Cannabis Rescheduling (2023).
[9] Drug Enforcement Administration Notice of Hearing on Ma*****na Rescheduling Proceedings (2026).
[10] Congressional Research Service. Federal Cannabis Reform: Economic, Banking, and Tax Implications.
*****na **p *****naFiji "
